Dexilant (Dexlansoprazole): Clinical Overview
Dexilant is a dual delayed-release proton pump inhibitor indicated for healing erosive esophagitis, maintaining healed erosive esophagitis, and treating symptomatic non-erosive GERD, with unique pharmacokinetics allowing flexible dosing without regard to meals or time of day 1.
Indications
Dexlansoprazole is FDA-approved for:
- Healing of erosive esophagitis (EE): All grades of severity
- Maintenance of healed erosive esophagitis: Prevention of relapse
- Symptomatic non-erosive GERD: Treatment of heartburn
The 2022 AGA guidelines specifically mention dexlansoprazole as a preferred option when standard PPIs fail, noting it as an "extended release formulation" that can be switched to once daily when patients have inadequate response to conventional PPIs 2. Recent meta-analyses confirm superior efficacy over placebo in achieving heartburn-free days and nights, particularly in patients with moderate to severe symptoms 3.
Dosing
Standard dosing:
- Healing erosive esophagitis: 60 mg once daily for up to 8 weeks
- Maintenance of healed EE: 30 mg once daily
- Symptomatic non-erosive GERD: 30 mg once daily for 4 weeks
Key dosing advantages:
- Can be taken without regard to meals or time of day (unlike conventional PPIs requiring 30-60 minutes before meals) 1
- The dual delayed-release mechanism provides two separate releases: first at pH 5.5, second at pH 6.8, extending acid suppression throughout the 24-hour period 4
- May replace twice-daily dosing of other PPIs with once-daily administration 5
Hepatic impairment adjustments 1:
- Mild (Child-Pugh A): No adjustment needed
- Moderate (Child-Pugh B): Reduce to 30 mg daily for healing EE
- Severe (Child-Pugh C): Not recommended (no data available)
Contraindications
Absolute contraindications 1:
- Known hypersensitivity to dexlansoprazole or any formulation component (can cause anaphylaxis, angioedema, bronchospasm, acute tubulointerstitial nephritis)
- Concurrent use with rilpivirine-containing products (significant drug interaction reducing rilpivirine efficacy)
Drug Interactions
Dexlansoprazole has a favorable drug interaction profile compared to other PPIs 6:
No clinically significant interactions with:
- Warfarin (no effect on INR or pharmacokinetics)
- Diazepam (CYP2C19 substrate)
- Phenytoin (CYP2C9 substrate)
- Theophylline (CYP1A2 substrate)
- Clopidogrel (safe coadministration) 7
Important interaction:
- Contraindicated with rilpivirine due to reduced antiretroviral efficacy 1
The drug is metabolized primarily by CYP3A and CYP2C19, but studies demonstrate it does not significantly inhibit or induce these pathways at therapeutic doses 6.
Adverse Effects
Common adverse effects (from 12-month safety data) 8:
- Upper respiratory infection (13-14%)
- Diarrhea
- Nausea
- Abdominal pain
- Flatulence
Serious but rare adverse effects 1:
- Hypertension (reported with 60 mg twice daily dosing)
- Hypersensitivity reactions (anaphylaxis, angioedema)
- Acute tubulointerstitial nephritis
- Clostridium difficile-associated diarrhea (class effect of PPIs)
- Bone fractures with long-term use (class effect)
- Hypomagnesemia with prolonged use
Pediatric considerations 1:
- In juvenile rat studies, high doses caused delayed growth and bone changes when initiated at postnatal day 7
- Heart valve thickening observed only at very high doses (2.1× pediatric exposure)
- Risk appears minimal in children ≥2 years of age
Laboratory monitoring:
- Serum gastrin levels rise with therapy (expected pharmacologic effect, not dose-related) 8
- No clinically meaningful changes in other laboratory parameters in 12-month studies
- No endocrine cell hyperplasia, adenocarcinoma, or lymphoma observed in gastric biopsies 8
Clinical Advantages
Dexlansoprazole offers specific benefits in:
- Nocturnal GERD and sleep disturbance: Extended acid suppression into nighttime hours 7
- Atypical GERD symptoms: Superior to lansoprazole for cough (76.5% vs 38.0% response) and globus (69.7% vs 30.8% response) in an 8-week trial 9
- Refractory symptoms: Maintains significantly higher pH levels in the 12-24 hour period compared to pantoprazole and esomeprazole 4
- Compliance concerns: Flexible dosing without meal timing requirements 10, 5
Overdose Management
Multiple doses up to 120 mg and single doses up to 300 mg did not cause death or severe adverse events. Hypertension is the primary serious concern with supratherapeutic dosing. Dexlansoprazole is not removed by hemodialysis; treatment is symptomatic and supportive 1.
Clinical Context
The 2022 AGA guidelines position dexlansoprazole as a second-line option when standard PPIs fail, specifically recommending switching to "more potent, less metabolized through CYP2C19 pathway, or available in extended release formulation" PPIs 2. The primary limitation remains cost, as generic PPIs are significantly less expensive, but dexlansoprazole provides a valuable option for patients with inadequate response to conventional therapy or those requiring simplified dosing for adherence 10.